Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
Hida AI, Sagara Y, Yotsumoto D, Kanemitsu S, Kawano J, Baba S, Rai Y, Oshiro Y, Aogi K, Sagara Y, Ohi Y. Hida AI, et al. Among authors: ohi y. Breast Cancer Res Treat. 2016 Jul;158(1):1-9. doi: 10.1007/s10549-016-3848-2. Epub 2016 Jun 3. Breast Cancer Res Treat. 2016. PMID: 27260189 Free PMC article.
Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinoma.
Kikuchi K, McNamara KM, Miki Y, Moon JY, Choi MH, Omata F, Sakurai M, Onodera Y, Rai Y, Ohi Y, Sagara Y, Miyashita M, Ishida T, Ohuchi N, Sasano H. Kikuchi K, et al. Among authors: ohi y. Breast Cancer Res Treat. 2017 Dec;166(3):709-723. doi: 10.1007/s10549-017-4464-5. Epub 2017 Aug 22. Breast Cancer Res Treat. 2017. PMID: 28831645
Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.
Sagara Y, Takada M, Ohi Y, Ohtani S, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M. Sagara Y, et al. Among authors: ohi y. Breast Cancer Res Treat. 2018 Oct;171(3):675-683. doi: 10.1007/s10549-018-4873-0. Epub 2018 Jul 3. Breast Cancer Res Treat. 2018. PMID: 29971625 Clinical Trial.
Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy.
Guestini F, Ono K, Miyashita M, Ishida T, Ohuchi N, Nakagawa S, Hirakawa H, Tamaki K, Ohi Y, Rai Y, Sagara Y, Sasano H, McNamara KM. Guestini F, et al. Among authors: ohi y. Breast Cancer Res Treat. 2019 Jan;173(2):275-288. doi: 10.1007/s10549-018-4985-6. Epub 2018 Oct 10. Breast Cancer Res Treat. 2019. PMID: 30306430
Significance of glucocorticoid signaling in triple-negative breast cancer patients: a newly revealed interaction with androgen signaling.
Kanai A, McNamara KM, Iwabuchi E, Miki Y, Onodera Y, Guestini F, Khalid F, Sagara Y, Ohi Y, Rai Y, Yamaguchi R, Tanaka M, Miyashita M, Ishida T, Sasano H. Kanai A, et al. Among authors: ohi y. Breast Cancer Res Treat. 2020 Feb;180(1):97-110. doi: 10.1007/s10549-020-05523-7. Epub 2020 Jan 27. Breast Cancer Res Treat. 2020. PMID: 31989378
220 results